Neurocrine Biosciences, Inc [NBIX] stock is trading at $154.8, up 0.68%. An important factor to consider is whether the stock is rising or falling in short-term value. The NBIX shares have gain 12.14% over the last week, with a monthly amount glided 11.30%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Neurocrine Biosciences, Inc [NASDAQ: NBIX] stock has seen the most recent analyst activity on October 21, 2025, when Citigroup initiated its Buy rating and assigned the stock a price target of $175. Previously, Truist started tracking the stock with Buy rating on July 21, 2025, and set its price target to $163. On July 10, 2025, Goldman initiated with a Buy rating and assigned a price target of $182 on the stock. Needham upgraded its rating to a Buy but stick to its price target of $138 on April 15, 2025. RBC Capital Mkts upgraded its rating to an Outperform but $137 remained the price target by the analyst firm on April 14, 2025. Deutsche Bank started tracking with a Hold rating for this stock on February 11, 2025, and assigned it a price target of $138.
Neurocrine Biosciences, Inc [NBIX] stock has fluctuated between $84.23 and $157.67 over the past year. Currently, Wall Street analysts expect the stock to reach $170.09 within the next 12 months. Neurocrine Biosciences, Inc [NASDAQ: NBIX] shares were valued at $154.8 at the most recent close of the market. An investor can expect a potential return of 9.88% based on the average NBIX price forecast.
Analyzing the NBIX fundamentals
Neurocrine Biosciences, Inc [NASDAQ:NBIX] reported sales of 2.68B for the trailing twelve months, which represents a growth of 27.78%. Gross Profit Margin for this corporation currently stands at 0.98% with Operating Profit Margin at 0.21%, Pretax Profit Margin comes in at 0.23%, and Net Profit Margin reading is 0.16%. To continue investigating profitability, this company’s Return on Assets is posted at 0.1, Equity is 0.16 and Total Capital is 0.15. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.14.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 153.23 points at the first support level, and at 151.65 for the second support level. However, for the 1st resistance point, the stock is sitting at 156.01, and for the 2nd resistance point, it is at 157.21.
Ratios To Look Out For
For context, Neurocrine Biosciences, Inc’s Current Ratio is 3.38. On the other hand, the Quick Ratio is 3.27, and the Cash Ratio is 0.53. Considering the valuation of this stock, the price to sales ratio is 5.75, the price to book ratio is 5.14 and price to earnings (TTM) ratio is 36.97.
Transactions by insiders
Recent insider trading involved RASTETTER WILLIAM H, Director, that happened on Nov 05 ’25 when 18000.0 shares were sold. Officer, Gano Kyle completed a deal on Nov 04 ’25 to buy 300.0 shares. Meanwhile, Director WILLIAM H. RASTETTER bought 18000.0 shares on Nov 05 ’25.
